AstraZeneca PLC (LSE: AZN) said European Commission has granted marketing authorisation for the oral anti-cancer drug IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) across all lines of therapy.
The authorisation is based on a submission package including two pivotal Phase III studies comparing IRESSA with chemotherapy, IPASS and INTEREST.
IRESSA acts by inhibiting the tyrosine kinase enzyme in the EGFR, thus blocking the transmission of signals involved in the growth and spread of tumours. A mutation in the EGFR is a characteristic occurring in 10-15 percent of lung cancers in non-Asians, and studies have shown that these types of tumours are particularly sensitive to IRESSA.
Anders Ekblom, executive vice president for development at AstraZeneca, said: “IRESSA is the first truly targeted treatment for lung cancer, and the EU marketing authorisation today represents an important step forward in the treatment of this devastating disease. For the first time, patients with EGFR mutation positive tumours will have a more effective and better tolerated alternative to chemotherapy as a first-line treatment.”
AstraZeneca has agreed to conduct a follow-up study to generate further data in a Caucasian NSCLC patient population and is currently in discussion with the European Medicines Agency (EMEA) to finalise the study design and endpoints.www.proactiveinvestors.co.uk
No comments:
Post a Comment